The Australian stock market experienced a downturn today, with the ASX 200 closing below the 8,600 mark, signaling a bearish start to the week amid sectoral headwinds. The index’s performance underscores prevailing market anxieties as it revisits a key support/resistance level.
The S&P/ASX 200 Index closed at 8,598.90, after a decline of 0.42% on the day. This marks a 1.1% decrease since the beginning of the week, reflecting a broad market pullback that has bled over from US market weakness. While the overall market sentiment was negative, certain stocks bucked the trend, some considerably so on fundamental news.
Droneshield Ltd (ASX: DRO) was a standout performer, surging 22.17% to close at $2.81. This increase is attributed to the company’s robust growth trajectory, with revenue increasing from $1.2 million in FY2018 to $57.5 million in FY2024 and a $50 million contract win from a European client. Challenger Ltd (ASX: CGF) also saw gains, rising 3.85% to $9.44, driven by its focus on expanding its annuities business. Virgin Australia Holdings Ltd (ASX: VGN) experienced a 3.75% increase to $3.32, aided by a recovery in domestic travel and strategic partnerships.
There were plenty of names in red territory on the day, with some faring worse than others.
Top Australian Brokers
- Pepperstone - Top Australian broker - Read our review
- eToro - Invest in ASX and international shares - Read our review
Life360 Inc (ASX: 360) plummeted 5.74% to $32.71 to be the worst performer on the day, amid increasing competition in the family tracking app market. Despite the pullback of 40% from October’s high, the shares continue to be an outperformer this year, up 44.8% on the period.
Resource stocks were particularly hard hit, with Paladin Energy Ltd (ASX: PDN) dropping 4.8% to $8.52, NexGen Energy Ltd (ASX: NXG) falling 4.79% to $12.91, and Yancoal Australia Ltd (ASX: YAL) declining 4.5% to $4.88. These declines reflect concerns over fluctuating uranium and coal prices, as well as increasing regulatory pressures on fossil fuels.
Telix Pharmaceuticals Ltd (ASX: TLX) also experienced a notable decrease of 4.63% to $12.56, hitting a new 52 week low at $12.47. This move has been influenced by setbacks in clinical trials and regulatory approvals that have now seen it’s share price lose 13.08% over the past week of trading, to sit 47% lower YTD.
The ASX 200’s dip below 8,600 suggests a cautious outlook for the near term, as the battle between bulls and bears for the level continues.
